The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ORGANIZATION
FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
Japan’s drug pricing reform package for FY2026 finalized late last year remains fundamentally oriented toward price reductions, albeit with some pro-industry improvements, including the abolition of the “spillover” rule, argues pharma leader Kenji Yasukawa. In a New Year interview with…
To read the full story
Related Article
- Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
- Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- FPMAJ Chair’s Call for Blanket Drug Price Hike: Bold Pitch or Wild Throw?
September 30, 2025
- FPMAJ Urges Blanket Drug Price Hikes to Offset Inflation: FY2026 Reform Talks
September 18, 2025
ORGANIZATION
- FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
January 6, 2026
- Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
- Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
- Generic Use Rate Rises Further to 89.5% in July-September: JGA
January 5, 2026
- Trade Groups Hail Spillover Abolition, but Urge Further Overhauls
December 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…